Related Experiment Video
Updated: Jan 10, 2026
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Preclinical Characterization of SDFZ-8, a Highly Potent HDAC1 Inhibitor, for Cancer Immunotherapy
Yi Zhou1,2, Jintong Du3, Xue Li1
1Department of Medicinal Chemistry State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead Compounds School of Pharmaceutical Science, Cheeloo College of Medicine, Shandong University Ji'nan Shandong China.
A new HDAC1 inhibitor, SDFZ-8, enhances antitumor immunity by increasing T cell activation and improving antigen presentation. Combining SDFZ-8 with PD-L1 blockade shows synergistic effects, offering a promising cancer immunotherapy strategy.
Area of Science:
- Oncology
- Immunology
- Medicinal Chemistry
Background:
- Histone deacetylases (HDACs) are crucial in cancer development and influence tumor immunity.
- Targeting HDACs offers a potential strategy for cancer treatment and immunotherapy.
Purpose of the Study:
- To discover and characterize novel HDAC1 inhibitors with potential in cancer immunotherapy.
- To evaluate the effects of a novel inhibitor, SDFZ-8, on tumor cells and the tumor immune microenvironment.
- To explore the synergistic potential of SDFZ-8 in combination with PD-L1 blockade.
Main Methods:
- Fragment-centric, structure-based drug design was used to identify SDFZ-8.
- In vitro assays assessed antiproliferative effects, histone acetylation, and apoptosis induction.
- In vivo studies evaluated antitumor immunity, including T cell activation, macrophage polarization, antigen presentation, and PD-L1 expression.
- Combination therapy with PD-L1 blockade was investigated.
Main Results:
- SDFZ-8 was identified as a potent HDAC1 inhibitor (IC50 = 0.4 nM) with strong antiproliferative activity.
- SDFZ-8 enhanced antitumor immunity by increasing T cell activation, M1 macrophage polarization, and antigen presentation, while reducing immunosuppression.
- SDFZ-8 upregulated PD-L1 expression in tumor cells and lymphocytes.
- Combination therapy with SDFZ-8 and PD-L1 blockade demonstrated synergistic antitumor effects.
Conclusions:
- SDFZ-8 is a novel HDAC1 inhibitor with potent anticancer and immunomodulatory properties.
- SDFZ-8 effectively targets tumor cells and enhances antitumor immunity.
- Combining SDFZ-8 with PD-L1 blockade represents a promising strategy to improve cancer immunotherapy efficacy.
